

Therapy Area	Target – ID	Target – Hit	Lead Series	Lead Optimisation	Pre-clinical	Clinical
Inflammation & Immunity	Medicinal supplement			AI diseases /		Type 1 Diabetes
	Novel reformulation (drug reprofile)			Acute pancreatitis and organ failure		
	Recombinant plasminogen and Fc-plasminogen (biologic)			Bleeding / haematological disorders		
	Potent, selective inhibitors of Kv1.3 channel (peptide)			Autoimmune diseases		
	S1P receptor modulators (drug)			IBD		
	Novel target for NLRP3 inflammasome (drug)			Inflammatory diseases		
Oncology	Dual-targeted PI3K/BET inhibitors (drug)			Haematological and solid cancers		
	Anti-CXCR1 mAb			Oncology, MDSC depletion		
	CLEC9A mAb vaccine delivery platform			Cancer		
	Inhibiting PTPN2 and PTPN1 to boost CAR T cell function			Solid tumour and haematological cancers		
	Targeted fusion protein (biologic)			Oncology		
	Anti-CCR8 mAb			Oncology, Treg depletion		
Infectious Disease	Antisense oligonucleotides targeting ACE2			Infectious diseases		
Respiratory Disease	CLEC9A mAb vaccine delivery platform			PAH, Infectious diseases		
Cardiovascular and Metabolic Diseases	Selective AT2 receptor agonists (peptide)			Renal, liver, kidney, lung and cardiac fibrosis		
	GC Rx inhibitors (drug)			Obesity		
	Anti-CX3CR1 mAb			NASH, CKD, Atherosclerosis		
	Anti-Cannabinoid Receptor 1 mAb			NASH		
	Novel target (drug)			Fibrosis		
	Novel target (drug)			Polycystic Kidney Diseases including ADPKD		
CNS	Extended release formulation (drug)			Neurological and neurodegenerative diseases		
	GPCR modulators (undisclosed target, drug)			Schizophrenia		
Regenerative Medicine	Induced Trophoblast Stem Cells (iTSC)			Regenerative medicine		
	iBlastoids (stem cells)			Cell therapies, drug screening and toxicity testing		
	'Corrected' iTSCs			Cell therapy, disease modelling, drug discovery, tox testing etc		
	Generation of insulin-producing cells (drug)			Type I and Type II diabetes		
	Skeletal muscle regeneration (biologic)			DMD and other dystrophies, acute muscle injuries		

NEXT GENERATION TECHNOLOGIES:

- Lipopeptide-based nanoparticle gene / mRNA delivery (therapeutic)
- Novel lipid nanoparticle gene / mRNA delivery systems (vaccine)
- Functionally tuneable peptide hydrogels (drug delivery)
- Antibody nanoparticle delivery system (drug delivery or imaging systems)
- GPCR inhibitor screening assay

DIAGNOSTICS / PROGNOSTICS:

- Biomarker diagnostic for diabetic kidney disease
- Multiplexed platform for immune response monitoring (allergy, infectious diseases)
- Allergen immunotherapy biomarkers
- Diagnostic for illicit drug testing